Antengene Completes $120 Million Series B for China Clinical Trials

Antengene, an innovative Shanghai biopharma, has completed a $120 million Series B financing led by Boyu Capital and FountainVest. The company intends to use the financing to fund China clinical trials of its in-licensed lead programs, ATG-008 and ATG-010 (selinexor), and other clinical-stage assets. It will also expand its pipeline through internal R&D and external partnerships as it prepares for commercial operations. In 2017, Antegene raised $21 million in an A round led by Qiming Venture. More details....

Share this with colleagues:

Original Article: Antengene Completes $120 Million Series B for China Clinical Trials

More From BioPortfolio on "Antengene Completes $120 Million Series B for China Clinical Trials"